cas 2711862-56-3|| where to buy 1,1-Dimethylethyl (2S)-2-[2-(2-bromo-4,6-difluorophenyl)acetyl]-1-pyrrolidinecarboxylate

Nom du produit:1,1-Dimethylethyl (2S)-2-[2-(2-bromo-4,6-difluorophenyl)acetyl]-1-pyrrolidinecarboxylate

IUPAC Name:tert-butyl (2S)-2-[2-(2-bromo-4,6-difluorophenyl)acetyl]pyrrolidine-1-carboxylate

: CAS：2711862-56-3; Formule moléculaire：C17H20BrF2NO3; Pureté：95%+

Unité d'emballage	Stock disponible	Prix($)	Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2711862-56-3 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:2711862-56-3; Formule moléculaire:C17H20BrF2NO3; Point de fusion:-; Code SMILES:C(CC1=C(Br)C=C(F)C=C1F)(=O)[C@H]2N(C(OC(C)(C)C)=O)CCC2; Densité:1.425±0.06 g/cm3

: Numéro de catalogue:CM1077689; Poids moléculaire:404.25; Point d'ébullition:435.7±45.0 °C; N° Mdl:; Stockage:

: Pyrrolidines; Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

: IAG933; IAG933 is a potent, selective, and first-in-class inhibitor from Novartis that directly inhibits the protein-protein interaction (PPI) between YAP/TAZ and TEAD. By blocking this PPI, IAG933 interferes with oncogenic functions downstream of the Hippo signaling pathway, particularly in mesothelioma and other tumors with NF2 loss-of-function mutations or YAP/TAZ fusions. This inhibition reduces transcriptional activity and induces cell death in cancer cells, leading to significant tumor regressions in xenograft models. Additionally, combining IAG933 preclinically with other targeted therapies (i.e., RTK, KRAS-mutant selective, and MAPK inhibitors) shows promise for improving the efficacy and durability of treatment responses. IAG933 is currently being evaluated in a Ph. I trial (NCT04857372) for solid tumors with Hippo pathway alterations.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.